Fighting food allergy: Current approaches

Annals of the New York Academy of Sciences

Volumn 1056, Issue , 2005, Pages 30-45

  Nieuwenhuizen, Natalie E ^a   Lopata, Andreas L ^b,c  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

CpG; Cytokines; DNA vaccine; Food allergy; Immunostimulatory DNA; Immunotherapy; Murine models; Natural therapy; Recombinant allergens

Indexed keywords

ALTRAKINCEPT; ANTIBIOTIC AGENT; BAY 16 9996; BERTILIMUMAB; CHINESE DRUG; CPG OLIGODEOXYNUCLEOTIDE; CYTOKINE; DNA VACCINE; FC RECEPTOR; FOOD ALLERGEN; GAMMA INTERFERON; GAMMA1B INTERFERON; GE2; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOLOGICAL ADJUVANT; IMMUNOSTIMULATING AGENT; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 13 ANTIBODY; INTERLEUKIN 13 RECEPTOR ALPHA1; INTERLEUKIN 4; INTERLEUKIN 5; MEPOLIZUMAB; MONOCLONAL ANTIBODY; OMALIZUMAB; PHOSPHORYL LIPID A; PROBIOTIC AGENT; R 112; RECOMBINANT ALLERGEN; RECOMBINANT INTERLEUKIN 10; RECOMBINANT PROTEIN; SB 240683; SCH 55700; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANAPHYLACTIC SHOCK; CLINICAL TRIAL; CONFERENCE PAPER; CPG ISLAND; DEATH; DESENSITIZATION; DNA SEQUENCE; ESCHERICHIA COLI; FOOD ALLERGY; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; LACTOBACILLUS CASEI; LACTOBACILLUS RHAMNOSUS; LISTERIA MONOCYTOGENES; MICROENCAPSULATION; MILK ALLERGY; NONHUMAN; PATHOPHYSIOLOGY; PEANUT ALLERGY; SALMONELLA MINNESOTA; TH1 CELL; TH2 CELL;

ARACHIS HYPOGAEA; BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; LACTOBACILLUS CASEI; LACTOBACILLUS RHAMNOSUS; LISTERIA MONOCYTOGENES; MURINAE; SALMONELLA ENTERICA SUBSP. ENTERICA SEROVAR MINNESOTA;

EID: 29744460649     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1352.003     Document Type: Conference Paper

References (165)

1. HELM, R.M. & A.W. BURKS. 2000. Mechanisms of food allersy. Curr. Opin. Immunol. 12: 647-653.
2. SAMPSON, H.A. 2003. Food allergy. J. Allergy Clin. Immunol. 111: S540-547.
3. SAMPSON, H.A. 2004. Update on food allergy. J. Allergy Clin. Immunol. 113: 805-819.
4. SAMPSON, H.A. 2004. Food-induced anaphylaxis. Novartis Found Symp. 257: 161-171.
5. SICHERER, S.H., A. MUNOZ-FURLONG & H.A. SAMPSON. 2004. Prevalence of seafood allergy in the United States determined by a random telephone survey. J. Allergy Clin. Immunol. 114: 159-165.
6. SKOLNICK, H.S. et al. 2001. The natural history of peanut allergy. J. Allergy Clin. Immunol. 107: 367-374.
7. BOCK, S.A., A. MUNOZ-FURLONG & H.A. SAMPSON. 2001. Fatalities due to anaphylactic reactions to foods. J. Allergy Clin. Immunol. 107: 191-193.
8. PERRY, T.T. et al. 2004. Distribution of peanut allergen in the environment. J Allergy Clin. Immunol. 113: 973-976.
9. MONERET-VAUTRIN, D.A. & G. KANNY. 2004. Update on threshold doses of food allergens: implications for patients and the food industry. Curr. Opin. Allergy Clin. Immunol. 4: 215-219.
10. MORISSET, M. et al. 2003. Thresholds of clinical reactivity to milk, egg, peanut and sesame in immunoglobulin E-dependent allergies: evaluation by double-blind or single-blind placebo-controlled oral challenges. Clin. Exp. Allergy 33: 1046-1051.
11. TURCANU, V., S.J. MALEKI & G. LACK. 2003. Characterization of lymphocyte responses to peanuts in normal children, peanut-allergic children, and allergic children who acquired tolerance to peanuts. J. Clin. Invest. 111: 1065-1072.
12. SCHADE, R.P. et al. 2003. The cow's milk protein-specific T cell response in infancy and childhood. Clin. Exp. Allergy 33: 725-730.
13. TIEMESSEN, M.M. et al. 2004. Cow's milk-specific T-cell reactivity of children with and without persistent cow's milk allergy: key role for IL-10. J. Allergy Clin. Immunol. 113: 932-939.
14. ANDRE, F., J. PENE & C. ANDRE. 1996. Interleukin-4 and interferon-gamma production by peripheral blood mononuclear cells from food-allergic patients. Allergy 51: 350-355.
15. NOMA, T. et al. 1996. Cytokine production in children outgrowing hen egg allergy. Clin. Exp. Allergy 26: 1298-307.
16. WILSON, D.R., M.T. LIMA & S.R. DURHAM. 2005. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 60: 4-12.
17. SCHMIDT-WEBER, C.B. & K. BLASER. 2004. Immunological mechanisms in specific immunotherapy. Springer Semin. Immunopathol. 25: 377-390.
18. VARNEY, V.A. et al. 2003. Usefulness of specific immunotherapy in patients with severe perennial allergic rhinitis induced by house dust mite: a double-blind, randomized, placebo-controlled trial. Clin. Exp. Allergy 33: 1076-1082.
19. + T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. J. Allergy Clin. Immunol. 97: 1356-1365.
20. WACHHOLZ, P.A. et al. 2002. Grass pollen immunotherapy for hayfever is associated with increases in local nasal but not peripheral Th1:Th2 cytokine ratios. Immunology 105: 56-62.
21. ROLLAND, J. & R. O'HEHIR. 1998. Immunotherapy of allergy: anergy, deletion, and immune deviation. Curr. Opin. Immunol. 10: 640-645.
22. NASSER, S.M. et al. 2001. Interleukin-10 levels increase in cutaneous biopsies of patients undergoing wasp venom immunotherapy. Eur. J. Immunol. 31: 3704-3713.
23. BUFE, A. et al. 2004. Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: a double-blind placebo-controlled study. Allergy 59: 498-504.
24. PASSALACQUA, G. et al. 2004. Efficacy and safety of sublingual immunotherapy. Ann. Allergy Asthma Immunol. 93: 3-12.
25. MA, S.H., S.H. SICHERER & A. NOWAK-WEGRZYN. 2003. A survey on the management of pollen-food allergy syndrome in allergy practices. J. Allergy Clin. Immunol. 112: 784-788.
26. HANSEN, K.S. et al. 2004. Food allergy to apple and specific immunotherapy with birch pollen. Molec. Nutr. Food Res. 48: 441-448.
27. BOLHAAR, S.T.H.P. et al. 2004. Efficacy of birch-pollen immunotherapy on cross-reactive food allergy confirmed by skin tests and double-blind food challenges. Clin. Exp. Allergy 34: 761-769.
28. KELSO, J.M. 2000. Pollen-food allergy syndrome. Clin. Exp. Allergy 30: 905-907.
29. BUCHER, X. et al. 2004. Effect of tree pollen specific, subcutaneous immunotherapy on the oral allergy syndrome to apple and hazelnut. Allergy 59: 1272-1276.
30. MITTAG, D. et al. 2004. Ara h 8, a Bet v 1-homologous allergen from peanut, is a major allergen in patients with combined birch pollen and peanut allergy. J. Allergy Clin. Immunol. 114: 1410-1417.
31. PONS, L. et al. 2004. Soy immunotherapy for peanut-allergic mice: modulation of the peanut-allergic response. J. Allergy Clin. Immunol. 114: 915-921.
32. OPPENHEIMER, J.J. et al. 1992. Treatment of peanut allergy with rush immunotherapy. J. Allergy Clin. Immunol. 90: 256-262.
33. NELSON, H.S. et al. 1997. Treatment of anaphylactic sensitivity to peanuts by immunotherapy with injections of aqueous peanut extract. J. Allergy Clin. Immunol. 99: 744-751.
34. BURKS, W., S.B. LEHRER & G.A. BANNON. 2004. New approaches for treatment of peanut allergy: chances for a cure. Clin. Rev. Allergy Immunol. 27: 191-196.
35. VAN REE, R. et al. 1996. Possible induction of food allergy during mite immunotherapy. Allergy 51: 108-113.
36. PAJNO, G.B. et al. 2002. Harmful effect of immunotherapy in children with combined snail and mite allergy. J. Allergy Clin. Immunol. 109: 627-629.
37. VALENTA, R. 2002. Recombinant allergen-based concepts for diagnosis and therapy of Type 1 allergy. Allergy 57: 66-67.
38. NIEDERBERGER, V. et al. 2004. Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc. Natl. Acad. Sci. USA 101: 14677-14682.
39. BOHLE, B. & S. VIETHS. 2004. Improving diagnostic tests for food allergy with recombinant allergens. Methods 32: 292-299.
40. VRTALA, S. et al. 2000. T cell epitope-containing hypoallergenic recombinant fragments of the major birch pollen allergen. Bet v 1. induce blocking antibodies. J. Immunol. 165: 6653-6659.
41. RENZ, H. 1999. How can animal models lead to improved specific immunotherapy (SIT)? Allergy 54: 39-40.
42. HERZ, U. et al. 1996. The relevance of murine animal models to study the development of allergic bronchial asthma. Immunol. Cell Biol. 74: 209-217.
43. HERZ, U., H. RENZ & U. WIEDERMANN. 2004. Animal models of type 1 allergy using recombinant allergens. Methods 32: 271-280.
44. HELM, R.M. & A.W. BURKS. 2002. Animal models of food allergy. Curr. Opin. Allergy Clin. Immunol. 2: 541-546.
45. HASELDEN, B.M., A.B. KAY & M. LARCHE. 2000. Peptide-mediated immune responses in specific immunotherapy. Int. Arch. Allergy Immunol. 122: 229-237.
46. NORMAN, P. S. 1996. Clinical experience with treatment of allergies with T cell epitope containing peptides. Adv. Exp. Med. Biol. 409: 457-461.
47. WILCOCK, L.K., J.N. FRANCIS & S.R. DURHAM. 2004. Aluminium hydroxide down-regulates T helper 2 responses by allergen-stimulated human peripheral blood mononuclear cells. Clin. Exp. Allergy 34: 1373-1378.
48. + dendritic cells. J. Immunol. 166: 5000-5007.
49. BAUER, S. et al. 2001. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc. Natl. Acad. Sci. USA 98: 9237-9242.
50. HARTMAN, G., G.J. Weiner & A.M. Krieg. 1999. CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. Proc. Natl. Acad. Sci. USA 96: 9305-9310.
51. STACEY, K.J. et al. 2000. Macrophage activation by immunostimulatory DNA. Curr. Top. Microbiol. Immunol. 247: 41-58.
52. CHU, R.S. et al. 1997. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J. Exp. Med. 186: 1623-1631.
53. LIANG, H. et al. 1996. Activation of human B cells by phosphorothioate oligodeoxynucleotides. J. Clin. Invest. 98: 1119-1129.
54. KLINE, J.N. et al. 1998. Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma. J. Immunol. 160: 2555-2559.
55. KLINE, J.N. et al. 1999. CpG oligodeoxynucleotides do not require TH1 cytokines to prevent eosinophilic airway inflammation in a murine model of asthma. J. Allergy Clin. Immunol. 104: 1258-1264.
56. SEREBRISKY, D. et al. 2000. CpG oligodeoxynucleotides can reverse Th2-associated allergic airway responses and alter the B7.1/B7.2 expression in a murine model of asthma. J. Immunol. 165: 5906-5912.
57. MAGONE, M.T. et al. 2000. Systemic or mucosal administration of immunostimulatory DNA inhibits early and late phases of murine allergic conjunctivitis. Eur. J. Immunol. 30: 1841-1850.
58. HORNER, A.A. et al. 2002. Immunostimulatory DNA-based therapeutics for experimental and clinical allergy. Allergy 57 (Suppl 72): 24-29.
59. TIGHE, H. et al. 2000. Conjugation of immunostimulatory DNA to the short ragweed allergen Amb a 1 enhances its immunogenicity and reduces its allergenicity. J. Allergy Clin. Immunol. 106: 124-134.
60. SIMONS, F.E. et al. 2004. Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA. J. Allergy Clin. Immunol. 113: 1144-1151.
61. MARSHALL, J.D. et al. 2001. Immunostimulatory sequence DNA linked to the Amb a 1 allergen promotes T(H)1 cytokine expression while downregulating T(H)2 cytokine expression in PBMCs from human patients with ragweed allergy. J. Allergy Clin. Immunol. 108: 191-197.
62. SANTELIZ, J.V. et al. 2002. Amb a 1-linked CpG oligodeoxynucleotides reverse established airway hyperresponsiveness in a murine model of asthma. J. Allergy Clin. Immunol. 109: 455-462.
63. TULIC, M.K. et al. 2004. Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response. J. Allergy Clin. Immunol. 113:235-241.
64. LI, X.M. et al. 2003. Persistent protective effect of heat-killed Escherichia coli producing "engineered," recombinant peanut proteins in a murine model of peanut allergy. J. Allergy Clin. Immunol. 112: 159-167.
65. LI, X.M. et al. 2003. Engineered recombinant peanut protein and heat-killed Listeria monocytogenes coadministration protects against peanut-induced anaphylaxis in a murine model. J. Immunol. 170: 3289-3295.
66. FRICK, O.L. et al. 2005. Allergen immunotherapy with heat-killed Listeria monocytogenes alleviates peanut and food-induced anaphylaxis in dogs. Allergy 60: 243-250.
67. BALDRICK, P., D. RICHARDSON & A.W. WHEELER. 2001. Safety evaluation of a glutaraldehyde modified tyrosine adsorbed housedust mite extract containing monophosphoryl lipid A (MPL) adjuvant: a new allergy vaccine for dust mite allergy. Vaccine 20: 737-743.
68. WHEELER, A.W., J.S. MARSHALL & J.T. ULRICH. 2001. A Th1-inducing adjuvant, MPL, enhances antibody profiles in experimental animals suggesting it has the potential to improve the efficacy of allergy vaccines. Int. Arch. Allergy Immunol. 126: 135-139.
69. DRACHENBERG, K.J. et al. 2001. A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy 56: 498-505.
70. MOTHES, N. et al. 2003. Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin. Exp. Allergy 33: 1198-2008.
71. STEVENSON, D.D. 2000. Approach to the patient with a history of adverse reactions to aspirin or NSAIDs: diagnosis and treatment. Allergy Asthma Proc. 21: 25-31.
72. STEVENSON, D.D. 2003. Aspirin desensitization in patients with AERD. Clin. Rev. Allergy Immunol. 24: 159-168.
73. LITWIN, A. et al. 1996. Immunologic effects of encapsulated short ragweed extract: a potent new agent for oral immunotherapy. Ann. Allergy Asthma Immunol. 77: 132-138.
74. TEPAS, E.C. et al. 2004. Clinical efficacy of microencapsulated timothy grass pollen extract in grass-allergic individuals. Ann. Allergy Asthma Immunol. 92: 25-31.
75. TANG, D.C., M. DEVIT & S.A. JOHNSTON. 1992. Genetic immunization is a simple method for eliciting an immune response. Nature 356: 152-154.
76. ULMER, J.B. et al. 1993. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259: 1745-1749.
77. HSU, C.H. et al. 1996. Immunoprophylaxis of allergen-induced immunoglobulin E synthesis and airway hyperresponsiveness in vivo by genetic immunization. Nat. Med. 2: 540-544.
78. RAZ, E. et al. 1996. Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. Proc. Natl. Acad. Sci. USA 93: 5141-5145.
79. YOSHIDA, A. et al. 2000. Advantage of gene gun-mediated over intramuscular inoculation of plasmid DNA vaccine in reproducible induction of specific immune responses. Vaccine 18: 1725-1729.
80. PENG, H.J. et al. 2002. Induction of specific Th1 responses and suppression of IgE antibody formation by vaccination with plasmid DNA encoding Der f 11. Vaccine 20: 1761-1768.
81. LEE, D.J. et al. 1997. Inhibition of IgE antibody formation by plasmid DNA immunization is mediated by both CD4+ and CD8+ T cells. Int. Arch. Allergy Immunol. 113: 227-230.
82. SATO, Y. et al. 1996. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 273: 352-354.
83. JILEK, S. et al. 2001. Antigen-independent suppression of the allergic immune response to bee venom phospholipase A(2) by DNA vaccination in CBA/J mice. J. Immunol. 166: 3612-3621.
84. HOCHREITER, R. et al. 2003. TH1-promoting DNA immunization against allergens modulates the ratio of IgG1/IgG2a but does not affect the anaphylactic potential of IgG1 antibodies: no evidence for the synthesis of nonanaphylactic IgG1. J. Allergy Clin. Immunol. 112: 579-584.
85. ADEL-PATIENT, K. et al. 2001. Genetic immunisation with bovine beta-lactoglobulin cDNA induces a preventive and persistent inhibition of specific anti-BLG IgE response in mice. Int. Arch. Allergy Immunol. 126: 59-67.
86. HARTL, A. et al. 2004. DNA vaccines for allergy treatment. Methods 32: 328-339.
87. ROY, K. et al. 1999. Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat. Med. 5: 387-391.
88. LUDWIG-PORTUGALL, I. et al. 2004. Prevention of long-term IgE antibody production by gene gun-mediated DNA vaccination. J. Allergy Clin. Immunol. 114: 951-957.
89. TODA, M. et al. 2000. Inhibition of immunoglobulin E response to Japanese cedar pollen allergen (Cry j 1) in mice by DNA immunization: different outcomes dependent on the plasmid DNA inoculation method. Immunology 99: 179-186.
90. KWON, S.S., N. KIM & T.J. YOO. 2001. The effect of vaccination with DNA encoding murine T-cell epitopes on the Der p 1 and 2 induced immunoglobulin E synthesis. Allergy 56: 741-748.
91. MAECKER, H.T. et al. 2001. Vaccination with allergen-IL-18 fusion DNA protects against, and reverses established, airway hyperreactivity in a murine asthma model. J. Immunol. 166: 959-965.
92. LEUNG, D.Y. et al. 2003. Effect of anti-IgE therapy in patients with peanut allergy. N. Engl. J. Med. 348: 986-993.
93. WENSING, M. et al. 2002. The range of minimum provoking doses in hazelnut-allergic patients as determined by double-blind, placebo-controlled food challenges. Clin. Exp. Allergy 32: 1757-1762.
94. HAMELMANN, E., C. ROLINCK-WERNINGHAUS & U. WAHN. 2003. Is there a role for anti-IgE in combination with specific allergen immunotherapy? Curr. Opin. Allergy Clin. Immunol. 3: 501-510.
95. Kuehr, J. et al. 2002. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J. Allergy Clin. Immunol. 109: 274-280.
96. www.rigel.com/rigel/pr_1091415726.
97. ZHU, D. et al. 2002. A novel human immunoglobulin Fc gamma Fc epsilon bifunctional fusion protein inhibits Fc epsilon R1-mediated degranulation. Nat. Med. 8: 518-521.
98. ZHANG, K. et al. 2004. Inhibition of allergen-specific IgE reactivity by a human Ig Fcgamma-Fcepsilon bifunctional fusion protein. J. Allergy Clin. Immunol. 114: 321-327.
99. KOPF, M. et al. 1993. Disruption of the murine IL-4 gene blocks Th2 cytokine responses. Nature 362: 245-248.
100. MAGNAN, A. et al. 2000. Relationships between natural T cells, atopy, IgE levels, and IL-4 production. Allergy 55: 286-290.
101. MOHRS, M. et al. 1999. Differences between IL-4- and IL-4 receptor alpha-deficient mice in chronic leishmaniasis reveal a protective role for IL-13 receptor signaling. J. Immunol. 162: 7302-7308.
102. BORISH, L.C. et al. 2001. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J. Allergy Clin. Immunol. 107: 963-970.
103. GRUNIG, G. et al. 1998. Requirement for IL-13 independently of IL-4 in experimental asthma. Science 282: 2261-2263.
104. WALTER, D.M. et al. 2001. Critical role for IL-13 in the development of allergen-induced airway hyperreactivity. J. Immunol. 167: 4668-4675.
105. WILLS-KARP, M. et al. 1998. Interleukin-13: central mediator of allergic asthma. Science 282: 2258-2261.
106. FALLON, P.G. et al. 2001. IL-13 overexpression predisposes to anaphylaxis following antigen sensitization. J. Immunol. 166: 2712-2716.
107. BASHIR, M.E. et al. 2002. An enteric helminth infection protects against an allergic response to dietary antigen. J. Immunol. 169: 3284-3292.
108. www.bioportfolio.com/news/cat_8.htm.
109. LECKIE, M.J. et al. 2000. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 356: 2144-2148.
110. PHIPPS, S. et al. 2004. Intravenous anti-IL-5 monoclonal antibody reduces eosinophils and tenascin deposition in allergen-challenged human atopic skin. J. Invest. Dermatol. 122: 1406-1412.
111. www.mediummune.com/pipeline/i19.asp.
112. http://www.cambridgeantibody.com/html/technology_products/ product_pipeline/cat_213_treatment_for_allergies_including_asthma.
113. VISSERS, J.L. et al. 2004. Allergen immunotherapy induces a suppressive memory response mediated by IL-10 in a mouse asthma model. J. Allergy Clin. Immunol. 113: 1204-1210.
114. FROSSARD, C.P. et al. 2004. Lymphocytes in Peyer patches regulate clinical tolerance in a murine model of food allergy. J. Allergy Clin. Immunol. 113: 958-964.
115. AKBARI, O., R.H. DEKRUYFF & D.T. UMETSU. 2001. Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen. Nat. Immunol. 2: 725-731.
116. LEE, H.O. et al. 2000. Interferon gamma induction during oral tolerance reduces T-cell migration to sites of inflammation. Gastroenterology 119: 129-138.
117. DUMONT, F.J. 2003. Therapeutic potential of IL-10 and its viral homologues: an update. Exp. Opin. Therapeutic Patents 13: 1551-1577.
118. + T cells by grass pollen immunotherapy. J. Allergy Clin. Immunol. 111: 1255-1261.
119. STEVENS, S.R. et al. 1998. Long-term effectiveness and safety of recombinant human interferon gamma therapy for atopic dermatitis despite unchanged serum IgE levels. Arch. Dermatol. 134: 799-804.
120. NOH, G.W. & K.Y. LEE. 1998. Blood eosinophils and serum IgE as predictors for prognosis of interferon-gamma therapy in atopic dermatitis. Allergy 53: 1202-1207.
121. BRYAN, S.A, et al. 2000. Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 356: 2149-2153.
122. LEE, S.Y. et al. 2001. Oral administration of IL-12 suppresses anaphylactic reactions in a murine model of peanut hypersensitivity. Clin. Immunol. 101: 220-228.
123. ZIMENT, I. & D.P. TASHKIN. 2000. Alternative medicine for allergy and asthma. J. Allergy Clin. Immunol. 106: 603-614.
124. NIGGEMANN, B. & C. GRUBER. 2003. Side-effects of complementary and alternative medicine. Allergy 58: 707-716.
125. BIELORY, L. & K. LUPOLI. 1999. Herbal interventions in asthma and allergy. J. Asthma 36: 1-65.
126. SRIVASTAVA, K.D. et al. 2005. The Chinese herbal medicine formula FAHF-2 completely blocks anaphylactic reactions in a murine model of peanut allergy. J. Allergy Clin. Immunol. 115: 171-178.
127. LI, X.M. et al. 2001. Food allergy herbal formula-1 (FAHF-1) blocks peanut-induced anaphylaxis in a murine model. J. Allergy Clin. Immunol. 108: 639-646.
128. FULLER, R. 1991. Probiotics in human medicine. Gut 32: 439-442.
129. DUGAS, B. et al. 1999. Immunity and probiotics. Immunol. Today. 20: 387-390.
130. KIRJAVAINEN, P.V. & G.R. GIBSON. 1999. Healthy gut microflora and allergy: factors influencing development of the microbiota. Ann. Med. 31: 288-292.
131. MATRICARDI, P.M. 2002. Probiotics against allergy: data, doubts, and perspectives. Allergy 57: 185-187.
132. VANDERHOOF, J.A. & R.J. YOUNG. 2004. Current and potential uses of probiotics. Ann. Allergy Asthma Immunol. 93: S33-S37.
133. PAGANELLI, R. et al. 2002. Probiotics and food-allergic diseases. Allergy 57 (Suppl 72): 97-99.
134. O'Sullivan, G.C. et al. 2005. Probiotics: an emerging therapy. Curr. Pharm. Des. 11: 3-10.
135. BROWN, A.C. & A. VALIERE. 2004. Probiotics and medical nutrition therapy. Nutr. Clin. Care 7: 56-68.
136. MIRAGLIA DEL GIUDICE, M., JR., M.G. DE LUCA & C. CAPRISTO. 2002. Probiotics and atopic dermatitis. A new strategy in atopic dermatitis. Dig. Liver Dis. 34 (Suppl 2): S68-S71.
137. SIMON, G.L. & S.L. GORBACH. 1984. Intestinal flora in health and disease. Gastroenterology 86: 174-193.
138. PESSI, T. et al. 2000. Interleukin-10 generation in atopic children following oral Lactobacillus rhamnosus GG. Clin. Exp. Allergy 30: 1804-1808.
139. PESSI, T. et al. 1998. Probiotics reinforce mucosal degradation of antigens in rats: implications for therapeutic use of probiotics. J. Nutr. 128: 2313-2318.
140. BASHIR, M.E. et al. 2004. Toll-like receptor 4 signaling by intestinal microbes influences susceptibility to food allergy. J. Immunol. 172: 6978-6987.
141. NOVERR, M.C. et al. 2005. Development of allergic airway disease in mice following antibiotic therapy and fungal microbiota increase: role of host genetics, antigen, and interleukin-13. Infect. Immun. 73: 30-38.
142. POHJAVUORI, E. et al. 2004. Lactobacillus GG effect in increasing IFN-gamma production in infants with cow's milk allergy. J. Allergy Clin. Immunol. 114: 131-136.
143. ROSENFELDT, V. et al. 2004. Effect of probiotics on gastrointestinal symptoms and small intestinal permeability in children with atopic dermatitis. J. Pediatr. 145: 612-616.
144. ROSENFELDT, V. et al. 2003. Effect of probiotic Lactobacillus strains in children with atopic dermatitis. J. Allergy Clin. Immunol. 111: 389-395.
145. KALLIOMAKI, M. et al. 2001. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet 357: 1076-1079.
146. KALLIOMAKI, M. et al. 2003. Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial. Lancet 361: 1869-1871.
147. LODINOVA-ZADNIKOVA, R., B. CUKROWSKA & H. TLASKALOVA-HOGENOVA. 2003. Oral administration of probiotic Escherichia coli after birth reduces frequency of allergies and repeated infections later in life (after 10 and 20 years). Int. Arch. Allergy Immunol. 131: 209-211.
148. BOLHAAR, S.T. et al. 2004. Efficacy of birch-pollen immunotherapy on cross-reactive food allergy confirmed by skin tests and double-blind food challenges. Clin. Exp. Allergy 34: 761-769.
149. HANSEN, K.S. et al. 2004. Food allergy to apple and specific immunotherapy with birch pollen. Mol. Nutr. Food Res. 48: 441-448.
150. LI, X.M. et al. 2003. Engineered recombinant peanut protein and heat-killed Listeria monocytogenes coadministration protects against peanut-induced anaphylaxis in a murine model. J. Immunol. 170: 3289-3295.
151. LI, X.M. et al. 2003. Persistent protective effect of heat-killed Escherichia coli producing "engineered," recombinant peanut proteins in a murine model of peanut allergy. J. Allergy Clin. Immunol. 112: 159-167.
152. SHIDA, K. et al. 2002. Lactobacillus casei strain Shirota suppresses serum immunoglobulin E and immunoglobulin G1 responses and systemic anaphylaxis in a food allergy model. Clin. Exp. Allergy 32: 563-570.
153. FROSSARD, C.P., C. HAUSER & P.A. EIGENMANN. 2001. Oral carrageenan induces antigen-dependent oral tolerance: prevention of anaphylaxis and induction of lymphocyte anergy in a murine model of food allergy. Pediatr. Res. 49: 417-422.
154. www.foodallergy.org/research/antiigetherapy.html.
155. WALKER, S. et al. 2004. Anti-IgE for chronic asthma in adults and children. The Cochrane Library, Issue 4.
156. www.pdl.com/applications/press_releases.cfm?newsId=68.
157. KIPS, J.C. et al. 2003. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study 164/rccm.200206-5250C. Am. J. Respir. Crit. Care Med. 167: 1655-1659.
158. FLOOD-PAGE, P et al. 2003. Anti-lL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J. Clin. Invest. 112: 1029-1036.
159. FITCH, N. et al. 2001. Preclinical evaluation of BAY 16-9966 a dual IL-4/IL-13 receptor antagonist. J. Allergy Clin. Immunol. 107: S61-S61.
160. ECONOMIDES, A.N. et al. 2003. Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat. Med. 9: 47-52.
161. www.regn.com/products/product_candidate.asp?v_c_id=8.
162. www.amrad.com.au/Filesa1%20-%20Aug%202004.pdf
163. ASADULLAH, K., W. STERRY & H.D. VOLK. 2003. Interleukin-10 therapy: review of a new approach. Pharmacol. Rev. 55: 241-269.
164. CHANG, T.T. & S.R. STEVENS. 2002. Atopic dermatitis: the role of recombinant interferon-gamma therapy. Am. J. Clin. Dermatol. 3: 175-183.
165. KALLIOMAKI, M. & E. ISOLAURI. 2003. Role of intestinal flora in the development of allergy. Curr. Opin. Allergy Clin. Immunol. 3: 15-20.